Postpartum depression (PPD) is one of the three major categories on the spectrum of postpartum psychiatric syndromes. Postpartum psychiatric syndromes are classified as either postpartum blues, postpartum depression, or postpartum psychosis. Postpartum depression is important to recognize clinically because of the effect it can have on the mother-child bond. The neurosteroid allopregnanolone, a progesterone derivative, is important for its role in positively modulating GABAA receptors. GABA-mediated signaling has been previously implicated in major depressive disorder. Allopregnanolone-mediated signaling has been identified as an important therapeutic target. Treatment with an allopregnanolone-analog, brexanolone, has been shown to improve depression scores in trials for the treatment of PPD. Brexanolone is a positive allosteric modulator of GABAA and is the first drug approved by the FDA to treat postpartum depression. Brexanolone enhances the inhibitory effects of GABAA, restores dysfunctional GABAA transmembrane channels, and mimics a naturally produced progesterone metabolite that fluctuates during pregnancy and postpartum. One open-label study and two phase two studies have some significant reduction in HAM-D scores after treatment and that the effect was still there 30 days post-treatment. Per the data reported, intravenous infusion of brexanolone could be efficacious and safe for the treatment of women suffering from postpartum depression.
<p class="abstract">This report intends to summarize the underlying pathophysiology, relevant symptoms, appropriate diagnostic workup, necessary imaging, and medical and surgical treatments of Sphenopalatine neuralgia (SN). This was done through a comprehensive literature review of peer-reviewed literature throughout the most relevant databases. Dr. Greenfield Sluder first observed that a number of his patients had atypical headaches that caused referred pain to the head and neck regions. The current understanding of the pathophysiology of SN states that irritation of the pterygopalatine ganglion secondary to inflammatory processes of the posterior ethmoid and sphenoid sinuses causes symptoms including unilateral persistent headache that begins lateral to the nose or near the eye and radiates across the face. Diagnosis is typically clinical; however, this is challenging due to lack of a definitive diagnostic criteria. Dr. Sluder originally treated his patients with 20-67% cocaine that was injected into the pterygopalatine ganglion to relieve the pain. Today, we use 88% phenol applied to the nasal mucosa. The most definitive way to both diagnoses and treat SN is the injection of cocaine or 88% phenol into the sphenopalatine region. The aim of the study was to update providers on the important clinical signs of SN and the important distinction between the clinically distinct conditions of sphenopalatine neuralgia and cluster headache. This report also outlines the treatment options to address this condition. </p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.